Table 2. The Association of Reproductive Hormones with Innate Antiviral Activity.

Group	Number	HSV-1 Suppression vs. Control (%)	HSV-2 Suppression vs. Control (%)	HIV-1 Suppression vs. Control (%)	Ratio of CVL Protein Content (Premenopausal: Postmenopausal)
Postmenopausal	29	23.22 ± 15.46	36.56 ± 29.36	10.96 ± 29.41*	1
Days 1-14	26	31.20 ± 15.91	40.23 ± 31.50	39.29 ± 40.57	2.2
Days 15-28	27	30.21 ± 29.38	39.26 ± 36.85	26.49 ± 38.45	2.6
OCP	27	28.09 ± 21.18	52.86 ± 24.42	35.77 ± 31.72	2.7
DMPA	28	31.95 ± 22.03	38.25 ± 41.61	32.95 ± 35.00	1.8
LNG-IUD	28	25.09 ± 26.34	48.18 ± 30.55	37.88 ± 37.22	3.1
P-Value**		0.63	0.38	0.04***	<0.001

^*One postmenopausal result outlier excluded.

^**P-value from one way analysis of variance

^***HIV-1 suppression was lower among postmenopausal women compared to reproductive-aged women (11% vs. 34%, respectively; P=0.002)